MUC5B and soft tissue sarcoma: Although these clinical trials investigating MG1-based therapies for adult solid tumours are restricted to patients over 18 years of age, a separate phase I study evaluating a herpes simplex virus-based OV in paediatric and young adult patients (aged 12 to 21), including patients with bone and soft tissue sarcomas, demonstrated safety profiles comparable to those seen in adult populations [75].